HistoryAbout Nobelpharma

2003JuneCompany establishment
AprilLicense agreement with Janssen (Lunabell®)
License agreement with Teva in USA (Nobelzin®)
2006MaySales alliance with Fuji Pharma (Lunabell®)
2007AprilSales alliance with Alfresa (Nobelzin®)
JuneLicense agreement with Novatech in France (talc)
JulySales alliance with Nippon Shinyaku (Lunabell®)
DecemberLicense agreement with Pfizer (fosphenytoin)
2008AprilLaunch of Nobelzin® for Wilson's disease
JulyLaunch of Lunabell® (mixed hormone)
DecemberLaunch of Nobelbar® for neonatal seizures and status epilepticus
2009MarchLicense agreement with Eisai (carmustine wafer for intracranial implantation)
NovemberOpening of Osaka office
2010JuneOpening of Tokyo, Nagoya, and Fukuoka offices
DecemberAdditional indication of Lunabell® (functional dysmenorrhea)
License agreement with Keocyt in France (streptozocin)
2011MarchSales alliance with Eisai (Fostoin®)
AprilOpening of Sapporo office
May
  • Opening of Sendai office
  • Co-development agreement with Nippon Boehringer (anhydrous caffeine)
SeptemberLicense agreement with Clinigen in UK (Foscavir®, antiviral chemotherapeutic)
2012January
  • Approval transfer from AstraZeneca (Foscavir®)
  • Launch of Fostoin® for status epilepticus and prevention of postoperative seizure, Co-promotion with Eisai
  • Opening of Tokyo Distribution Center
FebruaryLaunch of Foscavir® through direct sales
JuneLicense agreement with Pfizer (sirolimus)
2013JanuaryLaunch of Gliadel® for malignant glioma
Approval transfer from MSD (Indacin®, Cosmegen®)
FebruaryOpening of Kyoto office
June
  • The 10th Anniversary
  • Opening of Omiya and Yokohama offices
JulyOpening of Kobe office
September
  • Launch of Lunabell® tablets ULD for dysmenorrhea
  • Launch of Alabel® oral 1.5 g (aminolevulinic acid) for diagnosis of malignant glioma
December
  • Approval transfer to Eisai (Gliadel®)
  • Launch of Unitalc® for malignant pleural effusion
2014SeptemberCollaboration with SRI International on endometriosis drug development
December
  • Launch of Rapalimus®, world first drug for lymphangioleiomyomatosis (LAM)
  • Launch of Respia® for apnea of prematurity
2015February
  • Launch of Zanosar® for malignant tumor (gastroenteropancreatic neuroendocrine tumor)
  • Launch of Nobelzin® tablets
  • Received "the Japan Academic Society of Venture and Entrepreneurs Award"
OctoberSirolimus received the first "SAKIGAKE" fast-track designation for drugs
2016FebruaryTitanium Bridge received the first "SAKIGAKE" fast-track designation for medical devices
MayLicense agreement with Danish Serendex Pharmaceuticals A/S for Molgradex® for pulmonary alveolar proteinosis
NovemberMarketing approval transferred to Clinigen KK (Foscavir®)
2017FebruaryMr. Shiomura (President & CEO) won the Minister of Economic, Trade and Industry Prize at Japan Venture Awards 2017
Page top